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Section A - Multiple Choice Questions 
Total No of Marks for this section: 100 
The answers for this section MUST be written on the MCQ Answer Sheet provided. Answer 
ALL (60) questions. Some questions weigh one mark (indicated next to the question) all others 
weigh 2 marks each. Suggested Time allocation:  90 minutes 
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Section B 
Case Study Questions 
Total No of Marks for this section: 100 
 
This section must be answered in the Answer Booklet provided. 
Answer ALL questions, check marks allocated per each question. 
 
Marks for each section are indicated.  Suggested time allocation for Section B: 90 minutes 
 
 
Case Study 1 (10 marks)  
Mrs GH is a 64 year old post-menopausal woman with metastatic breast cancer. She has had 
several cycles of chemotherapy including previous anthracyclines and she had her third cycle 
of capecitabine 8 days ago. She is feeling a bit unwell and her husband thinks she is not at all 
her usual self 
a) What side effects she may be having? 
b) Should she take additional cycle of capecitabine? 
 
 
Case Study 2 (10 marks) 
Mrs BH a 53 year old post-menopausal mother of two teenage children. She was diagnosed 
with node positive early breast cancer. Her Oestrogen receptor was positive and 
Progesterone receptor was negative. She has recently completed six cycles of fluorouracil, 
epirubicin, cyclophosphamide, docetaxel and then commenced trastuzumab 
a) What is trastuzumab indicated regime? 
b) What are trastuzumab side effects? 
c) What other treatment should be considered? 
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Case Study 3 (10 marks) 
Mrs PQ is a 59 year old women, has non-small cell lung cancer. She has had a course of 
gemcitabine combined with carboplatin and now requires second line chemotherapy. The 
doctor suggested erlotinib. 
a) What is the class and MOA for erlotinib? 
b) What are the side effects of all her medications? 
c) What other treatment should be considered? 
 
 
Case Study 4 (10 marks) 
Mr BS a 67 year old man with a history of localised prostate cancer was reviewed by his 
oncologist. Mr BS was previously treated with radical radiotherapy and more recently 
several lines of hormonal therapy. His PSA has resin over the last 6 months and is now 
80ng/mL. It was 0.1 ng/mL when he completed radical radiation therapy. He also complains 
that his longstanding back pain controlled by low dose NSAIDs has now become much 
worse and is out of control. 
a) What is the most likely cause for BS back pain? 
b) What treatment options should be considered? 
c) Why does BS require a dental examination? 
 
 
Case Study 5 (30 marks) 
RJ, a 52-year-old woman with a history of hypertension, osteoarthritis, and hypothyroidism, 
presents to the clinic complaining of hot flushes, vaginal dryness, and insomnia. She states 
that she experiences approximately three hot flushes per day and is awakened from sleep at 
least three to four times a week in a “pool of sweat” requiring her to change her clothes and 
bed linens. Her symptoms began about 3 months ago, and over that time, they have worsened 
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to the point where they have become very bothersome. On questioning, she states her last 
menstrual period was 1 year ago. 
 
RJ’s workup reveals the following additional information:  
PJ medical history: 
- Osteoarthritis of the lower back for 5 years controlled on paracetamol 500 mg two 
tablets 3 to 4 times daily; hypertension since age 45, currently controlled; 
hypothyroidism since age 25, currently controlled  
Father medical history: 
- Alive with HTN and CHD (MI at age 60)  
- Mother medical history: 
- Alive with hypothyroidism and GORD 
- PJ social history:  
- Nurse; nonsmoker; drinks one to two glasses of red wine with dinner on the 
weekends; denies illicit drug use 
Medications:  
- Paracetamol 500 mg two tablets by mouth 3 to 4 times daily;  
- Irbesartan/HCTZ 300/12.5 mg once daily; 
- Thyroxin sodium 50 mcg by mouth once daily 
- Multivitamin by mouth once daily 
Symptoms:  
- (+) hot flushes, night sweats, vaginal dryness and itching; (+) insomnia, myalgias, 
bowel changes, weight gain, constipation 
- Vital Signs: BP 128/78, P 78, RR 16, T 37.0°C, wt 74.5 kg 
- Neck: Supple; no bruits, no adenopathy, no thyromegaly. 
- Breasts: Supple; no masses 
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- Abdomen: Soft, nontender, nondistended; (+) BS, no masses 
- Genitourinary: Pelvic examination normal except (+) mucosal atrophy 
- Fasting lipid levels: LDL 3.76 mmol/L, HDL 1.17 mmol/L, Triglycerides 2.26 
mmol/L 
 
a) Which of the patient’s symptoms and past medical history are consistent with 
menopause?  
b) What are the goals of treatment for this patient?     
c) Assess the patient’s risk factors for Depression, heart disease and breast cancer.  
d) Recommend non-pharmacologic and pharmacologic treatment for this patient. Justify 
your recommendations.        
 
 
Case Study 6 (30 marks) 
CB, a 52-year-old man with type II diabetes, coronary artery disease, hypertension, and 
dyslipidaemia returns to your clinic for follow-up on his chronic disease states. When 
reviewing his history, he describes problems with his erections. After further questioning, 
you determine that his dysfunction has progressively gotten worse over the last year. He is 
quite emotional and states that the problem is distressing and has caused significant marital 
discord. He wonders about “those ads on television” suggesting a pill. 
Medical history: 
Type II diabetes for 15 years; not controlled due to his stressful profession; he often works 
late, eats on the run, and has no time for exercise; Coronary artery disease; myocardial 
infarction with stent placement 6 months ago; Hypertension for 8 years, currently controlled  
Dyslipidaemia for 8 years, currently controlled 
Social history:  
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Works long hours as a business executive; drinks alcohol only occasionally; has a 20-pack 
per-year smoking history, but quit 6 months ago. 
Medications:  
Metformin 1,000 mg orally twice daily; Metoprolol XL 50 mg orally once daily; Lisinopril 
40 mg once daily; Simvastatin 20 mg orally once daily and Aspirin 81 mg once daily 
Symptoms:  
(−) Morning, nocturnal, or spontaneous erections suitable for intercourse; (−) nocturia, 
urgency, symptoms of prostatitis; (–) chest pain or anginal symptoms; (+) significant life 
stressors; (+) mild pain in feet 
Vital signs: 
BP 128/78 mm Hg, P 85 beats/min, RR 18 breaths/min, Wt 249 lb (113 kg), Ht 70 in (178 
cm) 
Genital/Rectal:  
Normal scrotum and testicles w/o masses; penis without discharge or curvature 
Laboratory results: 
Total cholesterol, LDL, HDL, triglycerides normal; HbA1c 8%; Total testosterone 24 nmol/L 
 
a) Based on the available information, how would you classify his erectile dysfunction 
(ED)? 
b) What are his risk factors for ED?   
c) Identify treatment goals for this patient and what is his cardiovascular risk? 
d) What pharmacologic and non-pharmacologic alternatives are available for this patient? 
e) Which of the available options will be your treatments of choice based on degree of 
invasiveness, side effects, ease of use, and side-effect profile?   
f) What are the safety and efficacy monitoring parameters for the chosen treatment? 
End of Exam Paper  
